Delivering a high dose of a vaccine against tuberculosis intravenously, instead of under the skin, greatly improves the drug’s ability to protect against the deadly disease, a new study finds.

PharmaJet’s Needle-free intradermal (ID) injection device ("Tropis ® ID") will be evaluated as delivery system for the tuberculin skin test (TST) in a clinical study conducted by REDE-TB. The study ...

As many as 67 percent of injection drug users in Tijuana test positive for tuberculosis infection. A study by researchers from the University of California, San Diego School of Medicine, in ...

Medicare Part B may cover the costs of a purified protein derivative (PPD) test if your healthcare professional deems it necessary to diagnose tuberculosis (TB) due to existing symptoms. A PPD test ...

The MarketWatch News Department was not involved in the creation of this content. -- PharmaJet's Needle-free intradermal (ID) injection device ("Tropis(R) ID") will be evaluated as delivery system for ...

PharmaJet ®, a company focused on improving the performance and outcomes of injectables through needle-free injection technology, announced that its partner, Brazilian Tuberculosis Research Network ...

PharmaJet, a company focused on improving the performance and outcomes of injectables through needle-free injection technology, announced that its partner, Brazilian Tuberculosis Research Network ...